Navigation Links
Ophthalmic Drugs: World Market Prospects 2012-2022

NEW YORK, May 2, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Ophthalmic Drugs: World Market Prospects 2012-2022

Report Details

How to find trends and revenue predictions for the ophthalmic drug industry

What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions.

This study investigates prescription drugs treating human eye diseases. It lets you assess forecasted sales trends at world market, therapeutic submarket, product and national level to 2022. 

How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? Our investigation gives you business research and analysis with sales forecasts. 

You also see forecasting of five submarkets to 2022, finding potential revenues: 

• Glaucoma treatments

• Anti-allergy, anti-inflammatory and anti-infective agents

• Retinal disorder treatments

• Dry eye treatments

• Other medicines.

Find coverage of the R&D pipeline too, by therapeutic area, assessing trends and outlooks.

What will happen next? The pharma industry will improve treatment of ocular disorders and increase revenues there. The R&D pipeline in ophthalmology is strong. Also, improved drug delivery and new formulations will be important.

Visiongain predicts that the world market for ocular drugs will grow strongly from 2012 to 2022. It will be stimulated by increasing prevalence of eye disorders among aging populations. Some national treatment markets will grow fast; others will expand slowly.

What are leading companies doing? Our work discusses Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies, evaluating prospects of the industry and market. 

Sustained-release ocular implants, gene therapy and RNA interference technology will influence R&D, as will neuroprotective agents for glaucoma. Pipeline developments have strong potential. In 2012, under-met treatment needs remain. 

What effects will competition have? New products - novel small molecules, generics and biologics - will change the sector. Many commercial opportunities for ophthalmic drugs exist, with high revenues possible to 2022. Our report shows and explains.

Revenue forecasts, market shares, developmental trends and discussions In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 120 tables and charts and six research interviews.Eight ways Ophthalmic Drugs: World Market Prospects 2012-2022 helps you In particular, our study gives you the following knowledge on the topic:

• Find potential revenues to 2022 for the world market and submarkets

• Discover revenue forecasts to 2022 for 20 leading products

• See market forecasting to 2022 for US, Japan, EU5, Brazil, China and India

• Assess leading companies, discovering activities and outlooks

• Review R&D, seeing pipeline trends by therapeutic area

• Investigate competition and opportunities influencing sales

• Find out what will stimulate and restrain the industry and market

• View opinions from our survey, interviews with external authorities.

There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains.

Gain business research and analysis now for eye disorder medications 

Our study is for everybody needing industry and market analyses for ophthalmic medicines. You find data, trends and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents 1. Executive Summary

1.1 Aims, Scope and Format of the Report

1.1.1 Chapter Outlines

1.2 Research and Analysis Methods

2. Ophthalmic Disorders and Treatments2.1 The Ophthalmic Drug Market2.2 Ophthalmic Disorders2.3 The Human Eye and the Vision Process2.4 Glaucoma2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma2.4.2 Closed Angle Glaucoma2.4.3 Secondary Glaucoma2.4.4 Congenital Glaucoma2.4.5 Normal Tension Glaucoma2.4.6 Ocular Hypertension2.4.7 Glaucoma Risk Factors2.4.8 Diagnosis of Glaucoma2.4.9 Prevalence of Glaucoma2.4.10 Treatment of Glaucoma2.4.11 Prostaglandins are the First-Line Treatment of Choice2.4.12 Second-Line Glaucoma Treatments2.4.13 Combination Treatments2.4.14 Laser Treatment2.4.15 Surgery (Trabeculectomy)2.5 Age-Related Macular Degeneration (AMD)2.5.1 Dry AMD2.5.2 Wet AMD 2.5.3 AMD Risk Factors2.5.4 Diagnosis of AMD2.5.5 Prevalence of AMD2.5.6 Treatment of AMD2.6 Diabetic Retinopathy2.6.1 Diagnosis of Diabetic Retinopathy2.6.2 Prevalence of Diabetic Retinopathy2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy2.6.4 Pharmaceutical Treatments2.7 Ophthalmic Allergies2.7.1 Allergic Conjunctivitis is the Most-Common Eye Allergy2.7.2 Ophthalmic Allergy Treatments2.8 Ophthalmic Inflammatory Disorders2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease2.8.2 Ophthalmic Inflammatory Drugs2.9 Ophthalmic Infections2.9.1 Types of Eye Infection2.9.2 Treatment of Eye Infections2.10 Dry Eye Syndrome2.10.1 Causes and Prevalence of Dry Eye Syndrome2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears2.10.3 Prescription-Only Drugs for Dry Eye are Limited2.10.4 Tear Augmenters (Punctal Plugs)

3. The World Ophthalmic Pharmaceutical Market, 2012-2022

3.1 The Ophthalmic Pharmaceutical Market in 2010 

3.1.1 The Anti-Glaucoma Segment had the Largest Market Share in 2010

3.1.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2010

3.1.3 Four Manufacturers Account for Over Half the Market

3.2 World Ophthalmic Pharmaceutical Market Forecasts, 2012-2022

3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market from 2010-2016

3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market from 2017-2022?

3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2012-2022

3.3.1 Retinal Disorders Will Power Growth from 2010-2016

3.3.2 Retinal Disorder Revenue Growth Will Continue from 2017-2020

3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma Drugs from 2020 to 2022

4. The Anti-Glaucoma Drug Market, 2012-20224.1 The Anti-Glaucoma Drug Market in 20104.1.1 Prostaglandin Analogues Led the Anti-Glaucoma Market in 20104.1.2 Xalabrands (Xalatan/Xalacom)4.1.3 Lumigan Franchise4.1.4 Cosopt/Trusopt4.1.5 Travatan Z4.1.6 Alphagan4.1.7 Combigan4.1.8 Azopt4.1.9 Extravan/Duotrav4.2 Anti-Glaucoma Market Forecasts, 2012-20224.2.1 Generic Competition Will Affect the Anti-Glaucoma Market from 2010-20164.2.2 Novel Anti-Glaucoma Drugs Will Drive Growth from 2017-20224.2.3 Xalabrands (Xalatan/Xalacom) Sales Forecast, 2012-20224.2.4 Lumigan Franchise Sales Forecast, 2012-20224.2.5 Cosopt/Trusopt Sales Forecast, 2012-20224.2.6 Travatan Z Sales Forecast, 2012-20224.2.7 Alphagan Sales Forecast, 2012-20224.2.8 Combigan Sales Forecast, 2012-20224.2.9 Azopt Sales Forecast, 2012-20224.2.10 Extravan/DuoTrav Sales Forecast, 2012-2022

5. The Ophthalmic Anti-Allergy/Inflammatory/Infective Drug Market, 2012-2022

5.1 The Ophthalmic Anti-Allergy/Inflammatory/ Infective Market in 2010

5.1.1 Patanol

5.1.2 Vigamox/Vegamox

5.1.3 TobraDex

5.1.4 Pataday

5.1.5 Cravit

5.1.6 Acular

5.1.7 Xibrom/Bromday

5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2012-2022

5.2.1 Innovation in the Anti-Allergy/Inflammatory/Infective R&D Pipeline

5.2.2 Patanol Sales Forecast, 2012-2022

5.2.3 Vigamox Sales Forecast, 2012-2022

5.2.4 TobraDex Sales Forecast, 2012-2022

5.2.5 Pataday Sales Forecast, 2012-2022

5.2.6 Cravit Sales Forecast, 2012-2022

5.2.7 Acular Sales Forecast, 2012-2022

5.2.8 Xibrom/Bromday Sales Forecast, 2012-2022

6. The Retinal Disorders Drug Market, 2012-20226.1 The Retinal Disorder Treatment Market6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorders Market6.1.2 Lucentis Took Control of the Retinal Disorder Market in 20106.1.3 Visudyne was the Second Highest Selling Retinal Disorder Drug in 20096.1.4 Lucentis has Sidelined Macugen but Faces Potent Threat from Avastin6.1.5 Allergan's Ozurdex, First Drug Therapy for Macular Oedema6.2 Retinal Disorder Market Forecasts, 2012-20226.2.1 Lucentis Will Drive the Retinal Disorder Market from 2010-20166.2.2 Novel Drugs and New Disease Treatments Will Drive Growth from 2017-20226.2.3 Lucentis Sales Forecast, 2012-20226.2.4 Visudyne Sales Forecast, 2012-2022

7. The Dry Eye Drug Market, 2012-2022 

7.1 The Dry Eye Drug Market in 2010

7.1.1 Restasis - Prescription Drug for Dry Eye

7.1.2 Allergan's Refresh Brand, including Celluvisc, is the Second-Best-Selling Dry Eye Product

7.1.3 Hyalein: Marketed in Japan and China

7.1.4 The OTC Market for Artificial Tears is Fragmented and Competitive

7.2 Dry Eye Market Forecasts, 2012-2022

7.2.1 Increased Sales of Dry Eye Prescription Drugs Forecasted from 2012-2016

7.2.2 Growth in the Dry Eye Market Will Decline after 2013

7.2.3 Restasis Sales Forecast, 2012-2022

7.2.4 Refresh Brand including Celluvisc: Sales Forecast, 2012-2022

7.2.5 Hyalein Sales Forecast, 2012-2022

8. Issues Affecting the Market for Ophthalmic Drugs, 2012-20228.1 SWOT Analysis of the Ophthalmic Drugs Market8.2 Strengths of the Ophthalmic Pharmaceutical Market8.2.1 Development of New Drug Delivery Methods and Formulations8.2.2 Intraocular Injections8.2.3 Sustained-Release Ocular Implants8.2.4 Gene Therapy and RNA Interference Technology8.2.5 New Ophthalmic Therapeutic Applications for Drugs 8.2.6 Development of Neuroprotective Anti-Glaucoma Medications8.3 Weaknesses of the Ophthalmic Pharmaceutical Market8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition 8.3.2 Avastin is Cannibalising Lucentis Revenues8.4 Opportunities for the Ophthalmic Pharmaceutical Market8.4.1 Aging of the World Population8.4.2 Increasing Prevalence of Diabetes and Other Health Challenges8.4.3 Increasing Prevalence of Eye Disorders8.4.4 Retinal Disorders Will Have the Most-Marked Increases in Prevalence8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders8.4.6 Reimbursement for Ophthalmic Pharmaceuticals8.5 Threats Facing the Ophthalmic Pharmaceutical Market8.5.1 Patient Compliance8.5.2 The Rate of Diagnosis for Eye Disorders is Low

9. National Markets for Ophthalmic Pharmaceuticals, 2012-2022

9.1 Ophthalmic Pharmaceuticals: Leading National Markets, 2010

9.2 Leading Developed-Country Ophthalmic Pharmaceutical Markets

9.2.1 The US Ophthalmic Pharmaceutical Market, 2012-2022

9.2.2 The Japanese Ophthalmic Pharmaceutical Market, 2012-2022

9.2.3 Leading European Ophthalmic Pharmaceutical Markets, 2012-2022

9.3 Emerging-Economy Ophthalmic Pharmaceutical Markets

9.3.1 Ophthalmic Pharmaceuticals in Developing Countries

9.3.2 The Chinese Ophthalmic Pharmaceutical Market, 2012-2022

9.3.3 The Indian Ophthalmic Pharmaceutical Market, 2012-2022

10. The Ophthalmic Pharmaceutical R&D Pipeline10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Agents10.2 The Anti-Glaucoma Pipeline10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development10.2.2 Taflotan/DE-085 (Santen/Asahi)10.2.3 Azarga (Alcon)10.2.4 PF-4217329 (Pfizer)10.2.5 Anecortave (Alcon)10.2.6 DNB-001 (Danube)10.2.7 BVT.28949 (Biovitrum)10.2.8 OT-730 (Othera/QLT)10.2.9 AL-37807 (Alcon/Novartis)10.2.10 QLT's Punctal Plug Delivery Technology10.2.11 PF-03187207 (NicOx/Pfizer)10.3 The Ophthalmic Anti-Allergy Pipeline10.3.1 Bepreve (ISTA/Senju)10.3.2 FOV1101/ Prednisporin (Fovea/CombinatoRx)10.3.3 DE-103 (Santen)10.4 The Ophthalmic Anti-Inflammatory Pipeline10.4.1 T-Pred (ISTA)10.4.2 AzaSite Plus/ASV-502 (InSite Vision)10.4.3 AzaSite Xtra/ISV-405 (InSite Vision)10.4.4 Durezol (Senju/Sirion Therapeutics/Alcon)10.4.5 Luveniq (Lux Biosciences)10.4.6 Simulect (Cerimon)10.4.7 EGP-437 (EyeGate Pharma)10.5 The Ophthalmic Anti-Infective Pipeline10.5.1 TobraDex ST (Alcon/Novartis)10.5.2 ISV-403/Besifloxacin (Bausch & Lomb)10.5.3 Moxifloxacin/Dexamethasone (Alcon/Novartis)10.5.4 Aganocide (Alcon/NovaBay)10.6 The Retinal Disease Pipeline10.6.1 Retinal Diseases Have the Richest Pipeline10.6.2 Arxxant (Eli Lilly/Alcon/Takeda)10.6.3 Vitrase/Vitragen (ISTA)10.6.4 Aflibercept/VEGF Trap-Eye (Regeneron/Bayer)10.6.5 Bevasiranib/Cand5 (OPKO)10.6.6 Atacand/TCV-116 (AstraZeneca/Takeda)10.6.7 Medidur (pSivida/Alimera Sciences/Pfizer)10.6.8 NT-501 (Neurotech)10.6.9 Microplasmin (ThromboGenics)10.6.10 Novadur/Sustained-Release Brimonidine (Allergan)10.6.11 RTP801i-14/PF-4523655/PF-655 (Quark/Silence/Pfizer)10.6.12 AGN-745/SIRNA-027 (Allergan/Merck & Co.)10.6.13 DARPin/MP0112 (Allergan)10.6.14 ATG-3 (CoMentis)10.6.15 OT-551 (Othera)10.6.16 Fenretinide (Sirion Therapeutics/ReVision)10.6.17 Pazopanib (GlaxoSmithKline)10.6.18 RPE65 Gene Therapy (Targeted Genetics)10.6.19 Zybrestat (OXiGENE/Symphony ViDA)10.7 The Dry Eye Pipeline10.7.1 Prolacria (Inspire/Allergan/Santen)10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics)10.7.3 Rebamipide (Otsuka/Acucela)10.7.4 DE-101/Rivoglitazone (Santen)10.7.5 Ecabet Sodium (ISTA)10.7.6 Remura (ISTA)10.7.7 SAR 1118 (SARcode)10.7.8 DE-110 (Santen)10.7.9 DE-089 (Santen)10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth Stimulators

11. Research Interviews with External Authorities

11.1 Professor Leonard Bielory, MD, Director, STARx Allergy and Asthma Centre, LLC, and Professor of Medicine, Paediatrics, Ophthalmology and Visual Sciences, and Centre for Environmental Prediction, Rutgers University, Springfield, NJ, USA

11.1.1 Anterior Inflammatory Disease: Under-diagnosed and Under-treated?

11.1.2 On Current Developments in Ocular Inflammation and Therapeutic Agents

11.1.3 On Future Treatments for Ophthalmic Inflammatory Disorders

11.1.4 R&D and Pipeline Developments

11.1.5 On Therapeutic Areas Offering Growth Opportunities

11.2 Dr Victor Chong, MD, FRCS, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Senior Lecturer in Ophthalmology, University of Oxford, Oxford Eye Hospital, Oxford, UK

11.2.1 Key Unmet Needs

11.2.2 Research and Development

11.2.3 Limitations of Ophthalmic Treatments

11.2.4 Challenges in the Development of Ophthalmic Drugs

11.2.5 Complexities Involved in Developing Ophthalmic Drugs

11.2.6 Growth Opportunities in the Ophthalmic Drug Market

11.2.7 Challenges Facing the Ophthalmic Pharmaceutical Industry

11.2.8 Main Regions Offering Growth Potential

11.2.9 Needs of Glaucoma Patients

11.2.10 Future Treatments for Glaucoma

11.2.11 Pipeline Developments from a Physician's Perspective

11.2.12 Prospects for Replacing Current Treatments

11.2.13 Novel Treatments for Ophthalmic Diseases

11.3 Dr Christopher Rhodes, PhD, Chief Technology Officer, SKS Ocular, San Diego, California, USA

11.3.1 Key Unmet Needs

11.3.2 Challenges Facing the Ophthalmic Pharmaceutical Industry

11.3.3 Limitations of Ophthalmic Treatments

11.3.4 On Ocular SKS and Ophthalmic Market

11.3.5 On R&D and Ophthalmic Market in the Future

11.3.6 On Therapeutic Areas Offering Growth Opportunity

11.4 Professor David T. Shima, PhD, Institute of Ophthalmology, University College London, UK

11.4.1 On the Role of VEGF in Retinal Disorders

11.4.2 On Candidate Molecule E10030

11.4.3 On Candidate Molecule JSM 6427

11.4.4 On New Sustained Release Formulations

11.4.5 On Delta-Notch Signalling

11.4.6 On Potential Clinical Crossovers Between Ophthalmology and Oncology

11.4.7 On Commercial and Clinical Possibilities in the Market

11.4.8 On the Possibilities of Research into the Endothelial Fenestra

11.5 Dr Paul Ashton, President and CEO, pSivida, Watertown, MA, USA

11.5.1 On the Challenge of Getting Drugs to the Retina

11.5.2 On pSivida's Drug Delivery Platforms

11.5.3 On Iluvien and DR/DME

11.5.4 On Implant Technology and Drug Delivery

11.5.5 On pSivida's Pipeline Products

11.5.6 On Lucentis, Avastin and VEGF-Trap

11.5.7 On Challenges of siRNA

11.6 Expert Interview 6: Authority from a Company in the Industry (Views Provided Anonymously)

11.6.1 Key Unmet Needs

11.6.2 Challenges Facing the Ophthalmic Sector

11.6.3 On Current Ophthalmic Treatments and their Effectiveness

11.6.4 On Opportunities in the Ophthalmic Sector

12. Conclusions of the Study12.1 Ophthalmic Pharmaceuticals: An Attractive Niche Market12.2 Ophthalmic Pharmaceutical Market Forecast to 202212.3 What Will Succeed in the Ophthalmic Pharmaceutical Market?12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest?

List of Tables

Table 2.1 Glaucoma Drug Types, 2012Table 2.2 AMD Drug Types, 2012Table 2.3 Ophthalmic Allergy Drug Types, 2012Table 2.4 Ophthalmic Inflammatory Disorder Drug Types, 2012Table 2.5 Ophthalmic Anti-Infective Drug Types, 2012Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Sales and Market Shares, 2010Table 3.2 Top 20 Ophthalmic Pharmaceutical Brands: Sales and Market Shares, 2010Table 3.3 Top 10 Ophthalmic Pharmaceutical Manufacturers: Sales and Market Shares, 2010Table 3.4 World Ophthalmic Pharmaceutical Market: Revenue Forecast, 2010-2016Table 3.5 World Ophthalmic Pharmaceutical Market: Revenue Forecast, 2017-2022Table 3.6 World Ophthalmic Pharmaceutical Market by Therapeutic Category: Revenue Forecasts, 2010-2016Table 3.7 World Ophthalmic Pharmaceutical Market by Therapeutic Category: Revenue Forecasts, 2017-2022Table 4.1 Leading Anti-Glaucoma Brands: Sales and Market Shares, 2010Table 4.2 World Anti-Glaucoma Market: Sales Forecast, 2010-2016Table 4.3 World Anti-Glaucoma Market: Sales Forecast, 2017-2022Table 4.4 Leading Anti-Glaucoma Brands: Sales Forecasts, 2010-2016Table 4.5 Leading Anti-Glaucoma Brands: Sales Forecasts, 2017-2022Table 5.1 Therapeutic Category Sales and Market Shares in the Ophthalmic Anti-Allergy/ Inflammatory/Infective Segment, 2010Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales and Market Shares, 2010Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2010-2016Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2017-2022Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales Forecasts, 2010-2016Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brands: Sales Forecasts, 2017-2022Table 6.1 Therapeutic Category Sales and Market Shares in the Retinal Disorders Segment, 2010Table 6.2 Leading Retinal Disorder Brands: Sales and Market Shares, 2010Table 6.3 World Retinal Disorder Market: Sales Forecast, 2010-2016Table 6.4 World Retinal Disorder Market: Sales Forecast, 2017-2022Table 6.5 Leading Retinal Disorder Brands: Sales Forecasts, 2010-2016Table 6.6 Leading Retinal Disorder Brands: Sales Forecasts, 2017-2022Table 7.1 Leading Dry Eye Brands: Sales and Market Shares, 2010Table 7.2 World Dry Eye Market: Sales Forecast, 2010-2016Table 7.3 World Dry Eye Market: Sales Forecast, 2017-2022Table 7.4 Leading Dry Eye Brands: Sales Forecasts, 2010-2016Table 7.5 Leading Dry Eye Brands: Sales Forecasts, 2017-2022Table 8.1 SWOT Analysis: Strengths and Weaknesses of the World Ophthalmic Drugs Market, 2012-2022Table 8.2 SWOT Analysis: Opportunities and Threats in the World Ophthalmic Drugs Market, 2012-2022Table 8.3 Some Patent Expiries for Ophthalmic Pharmaceuticals, 2009-2014Table 8.4 Ophthalmic Disorder Prevalence ForecastsTable 9.1 Leading National Markets for Ophthalmic Pharmaceuticals: Sales and Market Shares, 2010Table 9.2 Leading National Markets for Ophthalmic Drugs: Revenue Forecasts, 2010-2016Table 9.3 Leading National Markets for Ophthalmic Drugs: Revenue Forecasts, 2017-2022Table 10.1 Key Drugs in the Anti-Glaucoma Pipeline, 2012Table 10.2 Key Drugs in the Ophthalmic Anti-Allergy Pipeline, 2012Table 10.3 Key Drugs in the Ophthalmic Anti-Inflammatory Pipeline, 2012Table 10.4 Key Drugs in the Ophthalmic Anti-Infective Pipeline, 2012Table 10.5 Key Drugs in the Retinal Disease Pipeline, 2012Table 10.6 Key Drugs in the Dry Eye Pipeline, 2012Table 10.7 Key R&D Pipeline Drugs for Other Ophthalmic Indications, 2012

List of Figures

Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2010Figure 3.2 Top Ten Ophthalmic Pharmaceutical Manufacturers: Market Shares, 2010Figure 3.3 World Ophthalmic Pharmaceutical Market: Revenue Forecast, 2010-2022Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Shares and Revenue Forecasts, 2010-2022Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Revenue Forecasts, 2010-2022Figure 4.1 Leading Anti-Glaucoma Brands: Market Shares, 2010Figure 4.2 World Anti-Glaucoma Market: Sales Forecast, 2010-2016Figure 4.3 World Anti-Glaucoma Market: Sales Forecast, 2017-2022Figure 4.4 Leading Anti-Glaucoma Brands: Market Shares, 2016Figure 4.5 Xalabrands (Xalatan/Xalacom) Sales Forecast, 2010-2016Figure 4.6 Xalabrands (Xalatan/Xalacom) Sales Forecast, 2017-2022Figure 4.7 Lumigan Franchise Sales Forecast, 2010-2016Figure 4.8 Lumigan Franchise Sales Forecast, 2017-2022Figure 4.9 Cosopt/Trusopt Sales Forecast, 2010-2016Figure 4.10 Cosopt/Trusopt Sales Forecast, 2017-2022Figure 4.11 Travatan Z Sales Forecast, 2010-2016Figure 4.12 Travatan Z Sales Forecast, 2017-2022Figure 4.13 Alphagan Sales Forecast, 2010-2016Figure 4.14 Alphagan Sales Forecast, 2017-2022Figure 4.15 Combigan Sales Forecast, 2010-2016Figure 4.16 Combigan Sales Forecast, 2017-2022Figure 4.17 Azopt Sales Forecast, 2010-2016Figure 4.18 Azopt Sales Forecast, 2017-2022Figure 4.19 Extravan/DuoTrav Sales Forecast, 2010-2016Figure 4.20 Extravan/DuoTrav Sales Forecast, 2017-2022Figure 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2010Figure 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands: Market Shares, 2010Figure 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2010-2016Figure 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market: Sales Forecast, 2017-2022Figure 5.5 Patanol Sales Forecast, 2010-2016Figure 5.6 Patanol Sales Forecast, 2017-2022Figure 5.7 Vigamox Sales Forecast, 2010-2016Figure 5.8 Vigamox Sales Forecast, 2017-2022Figure 5.9 TobraDex Sales Forecast, 2010-2016Figure 5.10 TobraDex Sales Forecast, 2017-2022Figure 5.11 Pataday Sales Forecast, 2010-2016Figure 5.12 Pataday Sales Forecast, 2017-2022Figure 5.13 Cravit Sales Forecast, 2010-2016Figure 5.14 Cravit Sales Forecast, 2017-2022Figure 5.15 Acular Sales Forecast, 2010-2016Figure 5.16 Acular Sales Forecast, 2017-2022Figure 5.17 Xibrom/Bromday Sales Forecast, 2010-2016Figure 5.18 Xibrom/Bromday Sales Forecast, 2017-2022Figure 6.1 Therapeutic Category Market Shares in the Retinal Disorder Market, 2010Figure 6.2 Leading Retinal Disorder Brands: Market Shares, 2010Figure 6.3 World Retinal Disorder Market: Sales Forecast, 2010-2016Figure 6.4 World Retinal Disorder Market: Sales Forecast, 2017-2022Figure 6.5 Lucentis: Sales Breakdown, 2008-2011Figure 6.6 Lucentis Sales Forecast, 2010-2016Figure 6.7 Lucentis Sales Forecast, 2017-2022Figure 6.8 Visudyne Sales Forecast, 2010-2016Figure 6.9 Visudyne Sales Forecast, 2017-2022Figure 7.1 World Dry Eye Market: Sales Forecast, 2010-2016Figure 7.2 World Dry Eye Market: Sales Forecast, 2017-2022Figure 7.3 Restasis Sales Forecast, 2010-2016Figure 7.4 Restasis Sales Forecast, 2017-2022Figure 7.5 Refresh Brand including Celluvisc Sales Forecast, 2010-2016Figure 7.6 Refresh Brand including Celluvisc Sales Forecast, 2017-2022Figure 7.7 Hyalein Sales Forecast, 2010-2016Figure 7.8 Hyalein Sales Forecast, 2017-2022Figure 8.1 Global Population Aged Over 65, 2010-2025Figure 8.2 Population Aged 65 Years or Over in Leading National Ophthalmic Pharmaceutical Markets, 2009 and 2025Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030Figure 9.1 Leading National Ophthalmic Drug Markets: Market Shares, 2010Figure 9.2 Leading National Ophthalmic Drug Markets: Market Shares, 2016Figure 9.3 Leading National Ophthalmic Drug Markets: Market Shares, 2019Figure 9.4 Leading National Ophthalmic Drug Markets: Market Shares, 2022Figure 9.5 US and Japanese Ophthalmic Drug Markets: Revenue Forecasts, 2010-2022Figure 9.6 EU5, Brazilian, Indian and Chinese Ophthalmic Drug Markets: Revenue Forecasts, 2010-2022Figure 12.1 Ophthalmic Pharmaceutical Market: World Revenues by Therapeutic Category, 2010, 2012, 2016, 2018, 2020 & 2022Figure 12.2 Ophthalmic Pharmaceutical Market: Overall World Revenue, 2010, 2012, 2016, 2018, 2020 & 2022Figure 12.3 Ophthalmic Pharmaceuticals: Leading National Revenue Forecasts, 2010, 2012, 2016, 2018, 2020 & 2022 

Companies Listed

Acucela Alcon (Novartis)Alimera SciencesAllerganAmerican Academy of Ophthalmology (AAO) [US]American Society of Retina Specialists (ASRS) [US]ApotexAsahi Glass Association for Research in Vision and Ophthalmology AstraZeneca Bausch & Lomb Bayer BiovitrumBristol-Myers SquibbCan-Fite BioPharmaCerimon Pharmaceuticals Chugai Pharmaceutical Corp.CombinatoRx CoMentisDaiichi SankyoDanube PharmaceuticalsEli LillyEsteveEuropean Medicines Agency (EMEA/EMA)EyeGate Pharmaceuticals Eyetech PharmaceuticalsFood and Drug Administration (FDA) [US]Fovea PharmaceuticalsGalderma International SA (Nestlé and L'Oréal)Genentech GlaxoSmithKlineGruenenthalInSite Vision Inspire PharmaceuticalsISTA PharmaceuticalsJohnson & JohnsonKowa CompanyKyorin Pharmaceutical Co.Kyowa Hakko Kirin Corp.Laboratorios Sophia LEO Pharma Lux BiosciencesMeda PharmaceuticalsMerck & Co.Ministry of Health, Labour and Welfare [Japan]Moorfields Eye Hospital [UK]Mylan National Eye Institute (NEI) [US]National Health Service (NHS) [UK]National Institute for Health and Clinical Excellence (NICE) [UK]National Institutes of Health (NIH) [US]NeurotechNicOxNovaBay PharmaceuticalsNovartis Novex OphthotechOPKO Health OSI PharmaceuticalsOthera PharmaceuticalsOtsuka Pharmaceutical Corp.Oxford Eye Hospital [UK]OXiGENEPaladin Labs PfizerpSividaQLTQuark PharmaceuticalsRanbaxy LaboratoriesRegeneron PharmaceuticalsReVision TherapeuticsRocheRutgers University, Springfield, New Jersey [US]Santen Pharmaceutical Corp.Sanwa Kagaku Kenkyusho Corp.SARcode CorporationSenju Pharmaceuticals Shire PharmaceuticalsSirion TherapeuticsSirna Therapeutics SKS Ocular Sunesis Pharmaceuticals Symphony ViDATakeda PharmaceuticalsTargeted GeneticsTeva Pharmaceutical IndustriesThromboGenicsUniversity College of London (UCL), Institute of Ophthalmology [UK]University of Aston, Birmingham [UK] University of Oxford [UK]Watson Pharmaceuticals

 To order this report:Drug and Medication Industry: Ophthalmic Drugs: World Market Prospects 2012-2022

More  Market Research Report

Check our  Industry Analysis and Insights

Contact Nicolas:
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
2. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
3. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
4. Ophthalmic Pharmaceutical Drugs - A Global Market Perspective
5. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
6. Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015
7. Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
8. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
9. Reportlinker Adds Ophthalmic Therapeutic Drugs: Technologies and Global Markets
10. BD Completes Sales of Ophthalmic Systems Unit and Surgical Blades Product Platform
11. French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec
Post Your Comments:
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Allergan plc ... an agreement with the New York State ... 2 of the Sherman Act, and other statutes with the ... in February 2014, to cease marketing and selling the now ... of settlement, Allergan admits no liability, has released its counterclaims ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices ... show that delves into an array of issues that are presently affecting Americans. Dedicated ... open dialogue, this show is changing the subjects consumers focus on, one episode at ...
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... water accessible for all, Water For Empowerment ™ attracts volunteers together who ... clean water by empowering women as key stakeholders in the process. The non-profit ...
Breaking Medicine News(10 mins):